Increasing treatment options in indolent non-Hodgkin's lymphoma

Seminars in Oncology

Volumn 29, Issue 2 SUPPL. 6, 2002, Pages 2-6

  Solal Céligny, Philippe ^a,b  

^a CENTRE JEAN BERNARD   (France)

^b NONE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORAMBUCIL; CYCLOPHOSPHAMIDE; PREDNISONE; PROTEIN BCL 2; RECOMBINANT ALPHA2A INTERFERON; RITUXIMAB; VINCRISTINE;

ALOPECIA; BONE MARROW CELL; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CONFERENCE PAPER; DRUG EFFICACY; DRUG TOLERABILITY; FOLLICULAR LYMPHOMA; HUMAN; NAUSEA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RELAPSE; REMISSION; TREATMENT PLANNING; VOMITING;

EID: 0036260564     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/sonc.2002.32746     Document Type: Conference Paper

References (24)

1. The natural history of initially untreated low-grade non-Hodgkin's lymphomas
2. The treatment of indolent lymphomas: Watchful waiting v aggressive combined modality treatment
3. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alpha: A randomized study from the Groupe d'Etude des Lymphomes Folliculaires
4. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program
5. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20
6. Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells
7. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: Safety and efficacy of re-treatment
8. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: Clinical and molecular evaluation
9. Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma
10. Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin's lymphoma
11. Rituximab as first-line and maintenance therapy for patients (pts) with indolent non-Hodgkin's lymphoma (NHL)
12. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy
13. Immunochemotherapy in indolent non-Hodgkin's lymphoma
14. Phase II study of rituximab in combination with fludarabine in patients (pts) with low-grade or follicular B-cell lymphoma
15. Interferon-gamma induces CD20 expression on multiple myeloma cells via induction of Pu.1 and augments rituximab binding to myeloma cells
16. Effect of interferon-alpha on CD20 antigen expression of B-cell chronic lymphocytic leukemia
17. Doxorubicin-containing regimen with or without interferon alfa-2b for advanced follicular lymphomas: Final analysis of survival and toxicity in the Groupe d'Etude des Lymphomes Folliculaires 86 Trial
18. Role of interferon alfa-2b in the induction and maintenance treatment of low-grade non-Hodgkin's lymphoma: Results from a prospective, multicenter trial with double randomization
19. A meta-analysis (MA) of randomised trials evaluating the role of interferon (IFN) as treatment for follicular lymphoma (FL)
20. Combination immunotherapy of relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma with rituximab and interferon-alpha-2a
21. Rituximab (Mab-Thera) as single agent and in combination with interferon-α-2a as treatment of untreated and first relapse follicular or other low-grade lymphomas. Preliminary results of a randomised phase II study (M39035)
22. Beyond immunochemotherapy: Combinations of rituximab with cytokines IFN-2a and GM-CSF
23. MabThera (rituximab) plus CHOP is superior to CHOP alone in elderly patients with diffuse large B-cell lymphoma (DLCL): Interim results of a randomized GELA trial
24. Rituximab in combination with CHOP improves survival in elderly patients with aggressive non-Hodgkin's lymphoma